Skip to Main Content

Correction: An earlier version of this story and the headline incorrectly stated that PBMs did not play a role in a discrepancy over the price of the chemo drug Imatinib. Both the story and headline have been updated.

WASHINGTON — Congress blasted drug middlemen at a hearing Tuesday, with multiple lawmakers pointing to a huge discrepancy between how much a chemo drug costs at CVS and its price from Mark Cuban’s Cost Plus Drugs.


The chemo drug in question, Imatinib, costs a Tennessee state-employee plan $17,000 at CVS for a 60-day supply and just $72 at Cost Plus Drugs, though the state can’t buy from Cost Plus Drugs because it is out of the CVS Caremark network. Exactly what is driving that $17,000 price — like what specific pharmacy benefit manager tactics are at play — wasn’t explained at the hearing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.